Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
21 juin 2021 08h30 HE
|
Auris Medical AG
Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of...
Global Acute Lymphoblastic Leukemia (ALL) Clinical Landscape Market Report 2021 - Novartis has the Highest Number of Completed Clinical Trials with 47
18 juin 2021 05h28 HE
|
Research and Markets
Dublin, June 18, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...
NEW LEADING-EDGE TREATMENT FOR LEUKEMIA NOW OFFERED AT NICKLAUS CHILDREN'S HOSPITAL
10 juin 2021 09h54 HE
|
Nicklaus Children's Hospital
MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Nicklaus Children's Hospital is one of only a few pediatric hospitals in Florida, and the only one in South Florida, to offer the latest immune cell...
Worldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others
13 mai 2021 05h03 HE
|
Research and Markets
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time
10 mai 2021 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched a new, four-hour Acute Myeloid Leukemia (AML)...
Leukapheresis Market by Product, Leukopak, Indication, Application, End-user - Global Forecast to 2026
14 avr. 2021 07h33 HE
|
Research and Markets
Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple...
Global Acute Myeloid Leukemia (AML) Disease Analysis Report 2021: On Average, it Takes 10.8 Years from Phase I to Approval, Compared to 9.6 Years in the Overall Oncology Space
12 avr. 2021 06h48 HE
|
Research and Markets
Dublin, April 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous...
Outlook on the Chronic Myeloid Leukemia (CML) Treatment Global Market to 2029 - by Treatment Type and Geography
30 mars 2021 07h48 HE
|
Research and Markets
Dublin, March 30, 2021 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
Retired Cancer Doctor, Edward Arenson MD CWSP, Chronicles Inspiring 50-Year Career in Compelling New Memoir
25 janv. 2021 06h15 HE
|
XlibrisUS
DENVER, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Now at the end of his rich medical career, Edward Arenson MD CWSP, is sharing the touching and candid stories of his brave young patients as well as paying...
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
20 janv. 2021 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US,...